Cargando…

ATRT-26. The PI3k inhibitor Paxalisib combines with the novel HDAC1/3 inhibitor RG2833 to improve survival in mice bearing orthotopic xenografts of atypical teratoid/rhabdoid tumors

We previously identified high activation of mTORC1 and mTORC2 in AT/RT by immunohistochemistry of 18 primary tumors expanding over each molecular subgroup of AT/RT. Paxalisib is a highly brain-penetrant PI3k inhibitor acting upstream of mTORC1/2 to fully inhibit the activation of both complexes. Ong...

Descripción completa

Detalles Bibliográficos
Autores principales:	Findlay, Tyler, Malebranche, Kristen, Raabe, Eric, Eberhart, Charles, Rubens, Jeffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Atypical Teratoid Rhabdoid Tumor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164640/ http://dx.doi.org/10.1093/neuonc/noac079.025

Ejemplares similares

ATRT-05. Infants and newborns with atypical teratoid/rhabdoid tumors (ATRT) and extracranial malignant rhabdoid tumors: a unique and challenging population
por: Nemes, Karolina, et al.
Publicado: (2022)

ATRT-02. THE DUAL MTORC1/2 INHIBITOR, TAK-228 COMBINES SYNERGISTICALLY WITH THE BH3 MIMETIC, OBATOCLAX TO IMPROVE SURVIVAL IN MICE BEARING ORTHOTOPIC XENOGRAFTS OF AT/RT
por: Findlay, Tyler, et al.
Publicado: (2021)

ATRT-02. MEK/ERK SIGNALLING DEPENDENCY IN ATYPICAL TERATOID RHABDOID TUMOURS
por: Shi, Hui (Claire), et al.
Publicado: (2020)

ATRT-10. ATYPICAL TERATOID/RHABDOID TUMOR OF THE PINEAL REGION IN A PEDIATRIC PATIENT
por: Almeida, Carlos, et al.
Publicado: (2020)

ATRT-18. Atypical Teratoid/Rhabdoid Tumor in Children: Case Reports from Indonesia
por: Ramadhan, Diko Anugrah, et al.
Publicado: (2022)

ATRT-05. RESULTS OF MULTICENTER TRIAL CONCERNING THE TREATMENT OF CHILDREN WITH ATYPICAL TERATOID/RHABDOID TUMORS (ATRT) OF THE CENTRAL NERVOUS SYSTEM
por: Zheludkova, Olga, et al.
Publicado: (2020)

ATRT-07. HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AN ADULT PRESENTATION OF THE ATYPICAL TERATOID-RHABDOID TUMOR (ATRT)
por: Mrugala, Maciej, et al.
Publicado: (2020)

ATRT-06. Atypical Teratoid Rhabdoid Tumors (ATRT): results from a Single Institution in Brazil - São Paulo University
por: Barreto, Juliana Silveira, et al.
Publicado: (2022)

ATRT-09. IDENTIFICATION OF HUB GENES IN ATYPICAL TERATOID/RHABDOID TUMORS BY MULTIPLE-MICROARRAY ANALYSIS
por: Liu, Wei, et al.
Publicado: (2020)

ATRT-18. SHH-SUBTYPE ATYPICAL TERATOID/RHABDOID TUMORS ARE SELECTIVELY SENSITIVE TO GEMCITABINE TREATMENT
por: Metselaar, Dennis, et al.
Publicado: (2020)

ATRT-07. DEFINING LOST AND GAINED TRANSCRIPTIONAL REGULATORY NETWORKS IN ATYPICAL TERATOID RHABDOID TUMOR
por: Nesvick, Cody, et al.
Publicado: (2021)

ATRT-26. META-ANALYSIS OF TREATMENT MODALITIES IN METASTATIC ATYPICAL TERATOID/RHABDOID TUMORS IN CHILDREN
por: Underiner, Reena M, et al.
Publicado: (2020)

ATRT-04. INHERITED RHABDOID PREDISPOSITION SYNDROME: A CASE OF CHOROID PLEXUS CARCINOMA AND ATYPICAL TERATOID RHABDOID TUMOR IN SIBLINGS
por: Judd, Alexis, et al.
Publicado: (2020)

ATRT-01. UPREGULATION OF PROTEIN SYNTHESIS AND PROTEASOME DEGRADATION CONFERS SENSITIVITY TO PROTEASOME INHIBITOR BORTEZOMIB IN MYC-ATYPICAL TERATOID/RHABDOID TUMORS
por: Tran, Minh-Huy, et al.
Publicado: (2020)

ATRT-06. SMARCB1 LOSS DRIVEN NON-CANONICAL PRC1 ACTIVITY REGULATES DIFFERENTIATION IN ATYPICAL TERATOID RHABDOID TUMORS (ATRT)
por: Alimova, Irina, et al.
Publicado: (2020)

ATRT-30. RETROSPECTIVE ANALYSIS OF CHILDREN WITH ATYPICAL TERATOID RHABDOID TUMOR TREATED ACCORDING TO ACNS0333
por: Hoffman, Lindsey, et al.
Publicado: (2020)

ATRT-21. RHABDOID PREDISPOSITION SYNDROME: REPORT OF MOLECULAR PROFILES AND TREATMENT APPROACH IN THREE CHILDREN WITH SYNCHRONOUS ATYPICAL TERATOID/RHABDOID TUMOR AND MALIGNANT RHABDOID TUMOR
por: Shatara, Margaret, et al.
Publicado: (2020)

ATRT-01. IDENTIFICATION OF MICRORNA-BASED PROGNOSTIC BIOMARKERS AND CANDIDATE THERAPEUTIC AGENTS FOR ATYPICAL TERATOID/RHABDOID TUMOR
por: Zhang, Yang
Publicado: (2021)

ATRT-09. IDENTIFICATION OF POTENTIAL GENETIC DRIVERS OF METHOTREXATE (MTX) RESISTANCE IN ATYPICAL TERATOID RHABDOID TUMOURS (ATRT) THROUGH A GENOME-WIDE RNAI SCREEN
por: Kannappan, Sunand, et al.
Publicado: (2021)

ATRT-01. Reconstitution of cGAS/ STING pathway via epigenetic reprogramming leads to anti-viral inflammatory signaling in Atypical teratoid rhabdoid tumors (ATRTs)
por: Mangoli, Avani, et al.
Publicado: (2022)

ATRT-08. A PHASE II STUDY OF CONTINUOUS LOW DOSE PANOBINOSTAT IN PAEDIATRIC PATIENTS WITH MALIGNANT RHABDOID TUMORS/ATYPICAL TERATOID RHABDOID TUMORS
por: Wood, Paul, et al.
Publicado: (2020)

ATRT-17. A phase II study of continuous low dose panobinostat in paediatric patients with malignant rhabdoid tumours and atypical teratoid rhabdoid tumours.
por: Wood, Paul, et al.
Publicado: (2022)

ATRT-03. IDENTIFICATION OF microRNA-BASED PROGNOSTIC BIOMARKERS AND CANDIDATE THERAPEUTIC AGENTS FOR ATYPICAL TERATOID/RHABDOID TUMOR
por: Zhang, Yang, et al.
Publicado: (2020)

ATRT-22. Outcomes for children with recurrent atypical teratoid rhabdoid tumor: A single institution study with updated molecular and germline analysis
por: Carey, Steven S, et al.
Publicado: (2022)

ATRT-22. HIGH-THROUGHPUT DRUG SCREENING OF FDA-APPROVED CANCER DRUGS REVEALS POTENTIAL THERAPEUTIC APPROACHES FOR ATYPICAL TERATOID RHABDOID TUMOUR
por: Chong, Wai Chin, et al.
Publicado: (2020)

ATRT-16. THE PI3K INHIBITOR PAXALISIB COMBINES SYNERGISTICALLY WITH THE MEK INHIBITOR MIRDAMETINIB TO TARGET ATYPICAL TERATOID/RHABDOID TUMORS
por: Malebranche, Kristen, et al.
Publicado: (2023)

ATRT-06. RESULTS OF MULTICENTER TRIAL CONCERNING THE TREATMENT OF CHILDREN WITH ATYPICAL TERATOID RHABDOID TUMORS OF THE CENTRAL NERVOUS SYSTEM UNDER 3 YEARS OLD
por: Olga, Zheludkova, et al.
Publicado: (2021)

ATRT-02. Neuropsychological function in infant atypical teratoid/rhabdoid tumor versus low-grade glioma survivors reflects tumor malignancy and multimodal treatment
por: Traunwieser, Thomas, et al.
Publicado: (2022)

ATRT-05. REPURPOSED ANTI-MALARIAL QUINACRINE ACTIVATES P53 AND INHIBITS ATRT TUMORIGENICITY
por: Kaur, Harpreet, et al.
Publicado: (2021)

ATRT-17. TARGETING GLUTAMINE METABOLISM LOWERS METHYLATION POTENCIALS IN AT/RT AND SYNERGIZE WITH TAZEMETOSTAT
por: Nakata, Satoshi, et al.
Publicado: (2020)

ATRT-04. CORRELATION OF CLINICOPATHOLOGIC FEATURES AND CUMULATIVE INCIDENCE OF RELAPSE FOR PATIENTS WITH ATYPICAL TERATOID RHABDOID TUMOR ON ACNS0333: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP
por: Reddy, Alyssa, et al.
Publicado: (2021)

ATRT-23. THE DUAL mTORC1/2 INHIBITOR SAPANISERTIB DISRUPTS THE NRF2-MEDIATED STRESS RESPONSE AND COMBINES SYNERGISTICALLY WITH THE BH3 MIMETIC OBATOCLAX TO EXTEND AT/RT SURVIVAL
por: Parkhurst, Ashlyn, et al.
Publicado: (2020)

ATRT-13. DIFFERENT CELLS OF ORIGIN PAVE THE WAY FOR MOLECULAR HETEROGENEITY IN RHABDOID TUMORS
por: Graf, Monika, et al.
Publicado: (2020)

ATRT-09. COMBINATION OF THE PI3K INHIBITOR PAXALISIB WITH THE NUCLEOSIDE ANALOG GEMCITABINE ACTIVATES THE INTEGRATED STRESS RESPONSE AND EXTENDS SURVIVAL IN ORTHOTOPIC MODELS OF ATYPICAL TERATOID/RHABDOID TUMORS
por: Findlay, Tyler, et al.
Publicado: (2023)

ATRT-21. Contribution of germline mosaic alterations of SMARCB1 in rhabdoid tumor predisposition syndrome
por: Masliah-Planchon, Julien, et al.
Publicado: (2022)

ATRT-19. Functional genomics reveal distinct modulators of response to CDK4/6 inhibitors in ATRTs
por: Merk, Daniel, et al.
Publicado: (2022)

ATRT-11. PREVALENCE OF GERMLINE VARIANTS IN SMARCB1 INCLUDING SOMATIC MOSAICISM IN AT/RT AND OTHER RHABDOID TUMORS
por: Shirai, Ryota, et al.
Publicado: (2020)

ATRT-33. ENABLING RAPID CLASSIFICATION OF ATRT WITH NANOSTRING NCOUNTER PLATFORM
por: Ho, Ben, et al.
Publicado: (2020)

ATRT-27. COST-EFFECTIVE ASSAYS TO SUBGROUP ATRT IN THE DAILY ROUTINE
por: Lobon-Iglesias, María-Jesús, et al.
Publicado: (2020)

ATRT-24. CELL SURFACE PROTEOME ANALYSIS OF ATRT IDENTIFIES TARGETS FOR IMMUNOTHERAPY
por: Cole, Allison, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3o99dpsjt34g8flqfa3nvldom7